November 16, 2018

News

FDA Approves Pembrolizumab for Hepatocellular Carcinoma
SPT Staff
Pembrolizumab (Keytruda) is indicated for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.
FDA Approves Biosimilar to Neulasta for Myelosuppressive Chemotherapy
Kristen Coppock, MA, Editor
Udenyca (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. 
Tildrakizumab-asmn Now Available for Moderate-to-Severe Plaque Psoriasis
Jennifer Barrett, Associate Editor
Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults with plaque psoriasis who are candidates for systemic therapy or phototherapy. 
FDA Approves Dupilumab Add-on for Moderate-to-Severe Asthma
Kristen Coppock, MA, Editor
Dupixent approved as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older.
Talazoparib Approved by FDA for HER2-Negative Breast Cancer
Jennifer Barrett, Associate Editor
Talazoparib is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer.
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us